MolMed is a clinical stage biotechnology company focusing on research, development, manufacturing and clinical validation of cell & gene therapies for the treatment of cancer and rare diseases
Based on a dual business model leveraging on common technological assets, MolMed is able to manage from pure to clinical research, development, manufacturing and regulatory authorization, market access and pricing & reimbursement.
R&D, development and GMP manufacturing
MolMed conducts R&D cell and gene therapy projects on a proprietary diversified pipeline in clinical and preclinical stage both autologous and allogeneic (NK cells), targeting hematological and solid tumors.
Thanks to its own authorized facilities, MolMed offers GMP services for the development and manufacturing of cell & gene therapies in collaboration and with important international partners, offering resources and expertise covering preclinical to Phase III trials activities.
A team of professionals with extensive entrepreneurship, corporate and academic experience, ensuring a rich heritage of scientific and managerial skills.VIEW OUR TEAM
Carlo Incerti, President of MolMed since September 2018, graduated in Medicine and Surgery in 1984 at the University of Modena. He most recently held the position of Head of Global Medical Affairs at Sanofi Genzyme and Chief Medical Officer, with oversight of 4 therapeutic areas: oncology, immunology, multiple sclerosis and rare diseases. He is Member of the Board of EuropaBio, the European Association for Bioindustries, and member of the Governing Board of IMI (Innovative Medicine Initiative), the largest public-private venture in the area of healthcare research, founded in 2008 thanks to a collaboration between the European Commission and the association of the European pharmaceutical industries (European Federation of Pharmaceutical Industries and Associations - EFPIA), with the aim of fostering innovation in the drug research and development process to satisfy unmet medical needs.
Chief Executive Officer
Amministratore Delegato di MolMed
Dr. Riccardo Palmisano, CEO at MolMed since December 2015, graduated in Medicine in 1985 at Parma University. His career in the Italian pharmaceutical industry started in 1986 at Farmitalia Carlo Erba (1986), he then moved on to Gruppo Menarini (1988) where he contributed to the development and internationalisation of the first Italian pharmaceutical Group, becoming Director of the Pharmaceutical Division Italy in 1993 and General Manager at Lusofarmaco in 1995. His career in multinational companies started in 2000: he set up the Italian branch of Shire Pharmaceutical (2000), then he was appointed Vice President Commercial Retail Market in GlaxoSmithKline Verona (2003) and, lastly, Vice President & General Manager Italy at Genzyme (2005), a U.S. biotech company specialized in research and development of orphan drugs for rare diseases. After the acquisition of Genzyme by Sanofi he was appointed Director of Business Strategy and Development at Sanofi Italia (2012-2013).
During his career, he successfully launched a large number of important products in many therapeutic areas, in both retail and hospital markets, participated and supported several international projects, and successfully negotiated pricing and reimbursement for several innovative drugs with the Italian Authorities. In 2008, he joined Assobiotec, the trade association part of Federchimica, that brings together Italian biotech companies, becoming Vice President, responsible for biotech pharma and health, in 2010. In 2016, was appointed President of Assobiotec. Reappointed Assobiotec President for the three-year period 2019-2022; on April 2019 reappointed vice-President of Cluster Lombardo Scienze della Vita.
Chief financial officer
Mr. Calabrese joined MolMed in September 2018 as Chief Financial Officer, following an extensive and significant international experience in public companies and in the biopharmaceutical sector, starting from PriceWaterhouseCooper where he was employed for seven years working in Milan, Italy and Boston, MA where, he served several clients of the biotech field listed on NASDAQ and NYSE, and subsequently at Novuspharma S.p.A., a subsidiary of Cell Therapeutics, Inc. (NASDAQ: CTIC), as Accounting & Finance Manager. From 2005 to 2014 he worked in Gentium S.p.A. (NASDAQ: GEN) where he was instrumental to the listing of the company on Nasdaq, covering various roles including Senior Vice President and Chief Financial Officer and Chief Operating Officer, supervising all of the company's corporate operations. Following the acquisition of Gentium by Jazz Pharmaceuticals (NASDAQ: JAZZ), he worked as General Manager and Site Leader for the Italian Operation at the Italian branch. He was also member of the Board of Directors of Gentium S.p.A. Jazz Pharmaceuticals Italy S.p.A. and Jazz Healthcare Italy S.r.l
Chief Business Officer
Luca Alberici is Chief Business Officer since April 2015. He joined MolMed in 2006 and worked with growing responsibilities in R&D, contributing to the development of the Company’s “core” products and scouting and validation of potential drug candidates to enrich the portfolio. After a Master in Business Administration, he joined Bain & Company, a leading management consulting firm, where he was involved in strategic business planning, portfolio effectiveness, organization and process reengineering, due diligence and post-merger integration in healthcare and consumer good practices. Luca holds a Master degree in Medical, Molecular and Cellular Biotechnology from Vita-Salute San Raffaele University, a PhD in Cellular and Molecular Biology from the same institution and a Master In Business Administration from SDA Bocconi Milan.
Scientific Advisory Board
The MolMed Scientific Advisory Board (SAB) is an independent advisory body that offers a unique learning and international experience.VIEW OUR TEAM
MolMed's Founder and SAB President – Founding Member of the Scientific Council at European Research Council; Professor of Hematology at Vita-Salute University, San Raffaele Hospital, Milan, Italy
Malcolm K. Brenner,
Director of the Center for Cell and Gene Therapy at the Baylor College of Medicine, Houston, Texas, USA; Professor of Medicine and of Pediatrics at Fayez S. Sarofim (Baylor College of Medicine), Houston, Texas, USA.
Gian Pietro Dotti,
member of the UNC Lineberger Comprehensive Cancer Center, Professor of the Department of Microbiology and Immunology and Director of the UNC Lineberger Immunotherapy Program at the University of North Carolina - Chapel Hill, NC, USA
Professor of Hematology and Head of the Hematology and cellular therapy Department at the Saint-Antoine Hospital and University Pierre & Marie Curie, Paris, France
Deputy Chief, Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, NY, USA.